10:10:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-02 Kvartalsrapport 2024-Q1
2024-03-22 Halvårsutdelning NOVO B 6.4
2024-03-21 Årsstämma 2024
2024-01-31 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-09-13 Split NOVO B 1:2
2023-08-18 Halvårsutdelning NOVO B 6
2023-08-10 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-03-24 Halvårsutdelning NOVO B 8.15
2023-03-23 Årsstämma 2023
2023-02-01 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-12 Halvårsutdelning NOVO B 4.25
2022-08-04 Kvartalsrapport 2022-Q2
2022-05-04 Kvartalsrapport 2022-Q1
2022-03-25 Halvårsutdelning NOVO B 6.9
2022-03-24 Årsstämma 2022
2022-02-02 Bokslutskommuniké 2021
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-16 Halvårsutdelning NOVO B 3.5
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-05 Kvartalsrapport 2021-Q1
2021-03-26 Halvårsutdelning NOVO B 5.85
2021-03-25 Årsstämma 2021
2021-02-03 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-14 Halvårsutdelning NOVO B 3.25
2020-08-06 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-03-27 Halvårsutdelning NOVO B 5.35
2020-03-26 Årsstämma 2020
2020-02-05 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-08-16 Halvårsutdelning NOVO B 3
2019-05-03 Kvartalsrapport 2019-Q1
2019-03-22 Halvårsutdelning NOVO B 5.15
2019-03-21 Årsstämma 2019
2019-02-01 Bokslutskommuniké 2018
2018-08-18 Halvårsutdelning NOVO B 3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-02 Kvartalsrapport 2018-Q1
2018-03-23 Halvårsutdelning NOVO B 4.85
2018-03-22 Årsstämma 2018
2018-02-01 Bokslutskommuniké 2017
2017-11-01 Kvartalsrapport 2017-Q3
2017-08-18 Halvårsutdelning NOVO B 3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-03 Kvartalsrapport 2017-Q1
2017-03-24 Ordinarie utdelning NOVO B 4.60 DKK
2017-03-23 Årsstämma 2017
2017-02-02 Bokslutskommuniké 2016
2016-10-28 Kvartalsrapport 2016-Q3
2016-08-12 Halvårsutdelning NOVO B 3
2016-08-05 Kvartalsrapport 2016-Q2
2016-04-29 Kvartalsrapport 2016-Q1
2016-03-21 Halvårsutdelning NOVO B 6.4
2016-03-18 Årsstämma 2016
2016-02-03 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2015-04-30 Kvartalsrapport 2015-Q1
2015-03-20 Ordinarie utdelning NOVO B 5.00 DKK
2015-03-19 Årsstämma 2015
2015-01-30 Bokslutskommuniké 2014
2014-10-30 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-01 Kvartalsrapport 2014-Q1
2014-03-21 Ordinarie utdelning NOVO B 4.50 DKK
2014-03-20 Årsstämma 2014
2014-02-03 Bokslutskommuniké 2013
2014-01-02 Split NOVO B 1:5
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-08 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-21 Ordinarie utdelning NOVO B 18.00 DKK
2013-03-20 Årsstämma 2013
2013-02-04 Bokslutskommuniké 2012
2012-10-31 Kvartalsrapport 2012-Q3
2012-08-09 Kvartalsrapport 2012-Q2
2012-04-27 Kvartalsrapport 2012-Q1
2012-03-22 Ordinarie utdelning NOVO B 14.00 DKK
2012-03-21 Årsstämma 2012
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-04 Kvartalsrapport 2011-Q2
2011-04-28 Kvartalsrapport 2011-Q1
2011-03-24 Ordinarie utdelning NOVO B 10.00 DKK
2011-03-23 Årsstämma 2011
2011-02-02 Bokslutskommuniké 2010
2010-03-25 Ordinarie utdelning NOVO B 7.50 DKK
2007-12-03 Split NOVO B 1:2
2001-04-04 Split NOVO B 1:5
1997-01-02 Split NOVO B 1:2

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Novo Nordisk är en producent av insulin för diabetesbehandling. Utöver specialistkompetensen inom diabetes producerar bolaget läkemedel för hormonbehandling samt produkter för hemofili och blödningsrubbningar. Produkterna återfinns på en global marknad och säljs under separata varumärken. Bolaget grundades ursprungligen under 1923 och har sitt huvudkontor i Bagsværd.
2022-02-04 16:16:59

Bagsværd, Denmark, 4 February 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Members of Executive Management have participated in a long-term incentive programme consisting of a one-year performance period (2018) and a three-year vesting period (2019-2021). The shares allocated have on 2 February 2022 been transferred to current and former executives as specified below. No dividend has been paid to the executives during the one-year performance period or the three-year vesting period. For further information please see Novo Nordisk’s Remuneration Report 2021.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaha Kutay
2 Reason for the notification
a)Position/statusClosely related to Kasim Kutay, member of the Board of Directors
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionPurchase of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 694.00255 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


255 shares

DKK 694.00
e)Date of the transaction2022-02-02
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonLars Fruergaard Jørgensen
2 Reason for the notification
a)Position/statusPresident and CEO

b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)

c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0076,619 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


76,619 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue




1
Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonLars Fruergaard Jørgensen
2 Reason for the notification
a)Position/statusPresident and CEO

b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares

c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 695.9140,000 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


40,000 shares

DKK 695.91
e)Date of the transaction2022-02-02
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive vice president, International Operations
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0023,947 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


23,947 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonKarsten Munk Knudsen
2 Reason for the notification
a)Position/statusExecutive vice president, Chief Financial Officer
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0021,551 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


21,551 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonKarsten Munk Knudsen
2 Reason for the notification
a)Position/statusExecutive vice president, Chief Financial Officer
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 674.4010,000 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


10,000 shares

DKK 647.40
e)Date of the transaction2022-02-04
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonDoug Langa
2 Reason for the notification
a)Position/statusExecutive vice president, North America Operations
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0023,947 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


23,947 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonDoug Langa
2 Reason for the notification
a)Position/statusExecutive vice president, North America Operations
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 697.5512,113 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


12,113 shares

DKK 697.55
e)Date of the transaction2022-02-03
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonCamilla Sylvest
2 Reason for the notification
a)Position/statusExecutive vice president, Commercial Strategy & Corporate Affairs
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0021,551 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


21,551 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonCamilla Sylvest
2 Reason for the notification
a)Position/statusExecutive vice president, Commercial Strategy & Corporate Affairs
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 682.7910,000 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


10,000 shares

DKK 682.79
e)Date of the transaction2022-02-03
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonHenrik Wulff
2 Reason for the notification
a)Position/statusExecutive vice president, Product Supply, Quality & IT
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,

type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionOther transaction (transfer of shares in

accordance with long-term incentive

programme)
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 0.0023,947 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


23,947 shares

DKK 0.00
e)Date of the transaction2022-02-03
f)Place of the transactionOutside a trading venue

Definitions and background information:

Publication
Publication shall take place no later than three working days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000 (calculated individually).

Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers, sisters, parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or executive for a period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership, the managerial responsibilities of which are discharged by a board member/executive or by a person referred to in items 1)-3) above, or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially equivalent to those of such a person.

What is trading/transaction?
Trading is any kind of transaction, including shares and share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments and exercise of options.

What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?
Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock Exchange.

What is the volume and price of transaction and aggregated information?
The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction. In case of multiple transactions, when the transactions relate to the same financial instrument, are of the same nature, are executed on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is the weighted average price.

The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:  
Mette Kruse Danielsen+45 4442 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com


Company announcement No 08 / 2022